Patent 12133913 was granted and assigned to TARIS Biomedical on November, 2024 by the United States Patent and Trademark Office.
The present application provides methods of treating overactive bladder and methods of training or retraining bladder, prolonging symptom relief, improving the quality of life and/or neuronal remodeling in an individual having overactive bladder, by administering an effective amount of trospium locally to the bladder of the individual for at least about 24 hours.